Abstract

It was recently reported that when mosquitoes infected with P. berghei sporozoites feed on mice, they deposit approximately 100–300 sporozoites in the dermis. When we inoculate P. yoelii (Py) sporozoites intravenously (IV) into BALB/c mice, the 50% infectious dose (ID50) is often less than 3 sporozoites, indicating that essentially all Py sporozoites in salivary glands are infectious. Thus, it should only take the bite of one infected mosquito to infect 100% of mice. In human subjects, it takes the bite of at least 5 P. falciparum-infected mosquitoes to achieve 100% blood stage infection. Exposure to 1–2 infected mosquitoes only leads to blood stage infection in approximately 50% of subjects. If mosquitoes carrying Py sporozoites inoculate 100–300 sporozoites per bite, and 1 to 2 mosquito bites achieve 50% blood stage infection rates, then this would suggest that the majority of sporozoites inoculated by mosquitoes into the dermis are not responsible for a productive infection, or that a significant number of sporozoite-infected mosquitoes do not inoculate any sporozoites. The objective of this study was to determine if this is the case. We therefore studied the infectivity to mice of the bites of 1, 2, 4, or 5–8 Py-infected mosquitoes. The bite of one Py sporozoite-infected mosquito caused blood stage infection in 41.4% (12/29) of mice, two bites infected 66.7% (22/33), four bites infected 75% (18/24), and five to eight bites infected 100% (21/21). These findings demonstrate that inoculation of sporozoites by mosquito bite is much less efficient than IV inoculation of Py sporozoites by needle and syringe. Such data may have implications for determining the best route and dose of administration to humans of our attenuated P. falciparum sporozoite vaccine, the scientific basis of which is immunity by bites from irradiated infected mosquitoes, and suggest that the challenge is to develop a method of administration that approximates IV inoculation, not one that mimics mosquito bite.

Highlights

  • We are currently developing a metabolically active, nonreplicating Plasmodium falciparum sporozoite malaria vaccine (PfSPZ Vaccine) [1]

  • Five day-old heat-selected female A. stephensi mosquitoes were fed on 4–6 week-old HSD:ICR(CD-1H) mice (Harlan Bioproducts, Indianapolis, IN) infected with P. yoelii [4], and maintained for 14–17 days to allow for sporozoite development

  • Efficiency of Transmission of Infection by Mosquito Bite To determine the number of bites required for the establishment of asexual erythrocytic stage infection in mice, one to eight A. stephensi mosquitoes with P. yoelii sporozoites in their salivary glands were allowed to feed on the ventral surface of BALB/c mice for twenty minutes

Read more

Summary

Introduction

We are currently developing a metabolically active, nonreplicating (attenuated) Plasmodium falciparum sporozoite malaria vaccine (PfSPZ Vaccine) [1]. Fifteen of sixteen (94%) human volunteers exposed to the bites of greater than 950 irradiated Anopheles species mosquitoes with P. falciparum sporozoites in their salivary glands were protected against challenge by the bites of five mosquitoes infected with fully virulent P. falciparum sporozoites [2]. 3 doses of 750 radiation-attenuated P. yoelii sporozoites (total number of sporozoites = 2250) administered intravenously (IV) leads to between 90% and 100% protection against virulent challenge [3]. This level of protection can be achieved by intradermal or subcutaneous inoculation of the sporozoites, but more sporozoites are required.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call